First Time Attendee Annual Course Scholarship

What is the SGNA First Time Attendee Annual Course Scholarship?

The SGNA Novice Nurse/Associate scholarship has been established to financially assist newer SGNA members (less than two years of membership) with attendance at their first SGNA Annual Course. The scholarship is geared towards people who are new to the GI/Endoscopy field to give them a chance to experience the Annual Course and all it has to offer. Grants of will be awarded each spring to those members who meet the established criteria. The number and amount of grants awarded will depend upon funds available.

Scholarship funds will be sent to successful applications by check after the completion of the Annual Course. All applicants will be guaranteed the "early bird" registration rate if funds are not awarded.

Applicants are asked to respond to all questions and responses should reflect their interest and reasons for wanting to attend the Annual Course. Applicants who apply should be available to attend the Annual Course that year. All information submitted should apply January to December of the past year.

Eligibility:

You may be eligible for the SGNA First Time Attendee Annual Course Scholarship if: 1. The applicants must be an SGNA member, preference will be given if you have been a member of SGNA less than two years 2. This will be your first time attending the Annual Course 3. You must currently be employed as a caregiver in gastroenterology and be relatively new to the field, with a preference given to those with less than two years' experience. 4. You are attending the full course 5. You must actively support the goals and philosophy of SGNA.

You are ineligible if:

1. You have previously received a scholarship from SGNA. 2. You have attended an SGNA Annual Course in the past. 3. You are a member of the SGNA Board of Directors.

Guidelines for Completion Any individual interested in applying for this educational scholarship must complete the application and return by March 1st. SGNA First Time Attendee Annual Course Scholarship Application

All information is due to SGNA Headquarters no later than March 1. Applicants will be informed of the Committee's decision in mid-april Please submit to: SGNA Awards Committee 330 N Wabash Avenue, Suite 2000 Chicago, IL 60611-4267

Email: [email protected] Fax: 312.369.6694

Type or clearly print the information requested below

Name and Credentials: _____Amal Adam Ibrahim______

Email: [email protected]______Phone: ______

Home address: ______Ribat National Hospital______

City: ______Khartoum______State: ___Sudan______ZIP: ____1095______

Employer: ______Head nurse______

Employer's Address: ______Ribat National Hospital Researchers present inner workings of Ebola vaccine trial UNIVERSITY OF FLORIDA

GAINESVILLE, Fla. -- An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus.

This is according to two researchers who will discuss their experimental Ebola vaccine trial during the American Association for the Advancement of Science's annual meeting today (Friday, Feb. 12, 2016).

Their discussion will focus on interim results of a study published in The Lancet in July. The study examined an experimental Ebola vaccine as well as a way of deploying the vaccine. The strategy includes vaccinating people who had contact with people who contracted Ebola and also the close contacts of people who had that contact -- an approach known as ring vaccination. Ring vaccination was first used in the 1970s to eradicate smallpox. University of Florida researcher Ira Longini, Ph.D., one of the study's authors, and lead author Ana Maria Henao Restrepo, M.D., a medical officer for the World Health Organization, expect the vaccination strategy could be used to combat other emerging pathogens. It works off the concept of surveillance and containment, and can be designed for interventions other than vaccination, including disease prevention and treatment.

"This type of analysis is a very robust design. It worked for the Ebola vaccine, and could work for the Zika vaccine, or any other emerging threat we might see," Longini said. "Now, we want to make the point that we can almost certainly contain future Ebola outbreaks, and that we will probably have a new paradigm and tool for dealing with new outbreaks of whatever emerges in the future."

Longini, a biostatistics professor in the UF colleges of Public Health and Health Professions and Medicine and director of the UF Center for Statistics and Quantitative Infectious Diseases, will highlight the study's unique design and results of the trial. Because researchers were working in an emergency situation, conducting a standard randomized controlled trial -- a trial in which study participants are randomly divided into two groups, one who receives the drug being tested and one who receives a placebo -- could have been unethical.

"When you're studying a vaccine for Food and Drug Administration licensure, you would normally like to run the vaccine through a double-blind, randomized placebo-controlled trial," said Longini, also a member of the UF Emerging Pathogens Institute. "To use a placebo in a situation like this Ebola epidemic, in which the probability of someone falling ill and dying is high, could be unethical."

For the researchers' interim results, the study included 7,651 people, more than 3,500 of whom were vaccinated. Researchers found the vaccine 100 percent effective in preventing Ebola illness in vaccinated people and 75 percent effective in reducing the risk of Ebola illness in rings where about half of the people had been vaccinated.

The researchers plan to publish their final paper examining the trial soon, but the trial is still ongoing to deliver ring vaccination for any new clusters of Ebola, including a current cluster in Sierra Leone. The researchers also plan to study how long a vaccinated person's immunity to Ebola lasts.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.______Provide the name and phone number of your immediate supervisor: ______Fatima Hussein 00249912140973 [email protected]______

May we contact him/her for information if needed? Yes ☐ No ☐ yes

1. Membership: 1a. How long have you been a member of SGNA? _2003about 12 year______

1b. Name and/or number of your Regional Society: ______Sudanese assosiation of GIT and endoscopy nurses ______

2. When did you begin working in a GI/Endoscopy facility? ______Since 1995______

3. List any SGNA-related (regional/local) activities you attended in the past two years: ______About 7-8 reigonal conferances and work shops______

4. Have you served as an officer or on a committee for your regional or local SGNA? Please list.

______Vice presidend of our ______regional society______

5. Essay: In 300 words or less (typed and double-spaced), explain why you want to go to the Annual Course and how you will share your experience with others.

Iam Amal Ibrahim My role is head nurse of endoscopy nurse at Ribat University Hospital We have a brand new endoscopy unit with diagnostic and theraputic capabilites . At my time in our unit I would like to be trained in all aspects of therputic gastroscopies ,colonscopies ,brochoscopies ,capsule endoscopy , dialitation , ERCP, EUS , EBUS and others. I would like to know the patient pathway and the role of endoscopy nurse in preassessment in different endoscopy procedures and the recovery and the final discharge of the patient . I would like to see your training package on the effects of sedation on the conscience patient include monitoring of the patient ,the use of oxygen and how to deal with emergancy situation. Another area of interest in your policies on infection control in other endoscopy units which could inculde mode of transmission ,causes of infection transmission with emphaises on prevention of patient to staff transmission , patient to patient transmission and enviroment to to patient transimission . As a senior nurse here I would be interested in knowing training and mentoring programme you use for all staff too endoscopy as I would like to have a simlilar programme in Sudan. This should include tge inital training pachage and the contiuing assessement of all grades of staff . One of the real goals I would like to have is to set up train the trainers programme for the GIT and endoscopy nursing staff in SUDAn, and this would be away of me to using my new knowlege and skills to benifit NOT only my unit but for whole of the endoscopy profession here in SUDAN. It would be wonderful to meet any of your endoscopy nurses who have been involved in this sort of training . As a leading member of sudanese association of gastroentrology and endoscopy nurses (S.A.G.E.N) all of this goals I hope will further the development of all the nurses working in SUDAN in GIT and endoscopy units. As I hope to feed back all my new knowlege at our yearly endoscopy nurses workshop in khartoum . Thank you for considering me for this course. 6. References: Please submit two references from a supervisor, certified nurse, or physician with whom you work on a regular basis.

1. NameDr Fatima Hussein Salimer text.

[email protected]@yahoo.comck here to enter text.

Phone;00249912140973re to enter text.

2. Name:Dr Amira Abasshere to enter text. Email:[email protected] Click here to enter

text. Phone;00249123373157lick here to enter text.

I understand that, if I receive an SGNA Novice Nurse/Associate Scholarship I am required to apply funds received toward expenses related to attending this annual course. I agree to complete a questionnaire of this scholarship program and return it within 30 days following the completion of the course (Questionnaire to be mailed after check has been issued). I agree to return to the SGNA any unused portion of the scholarship.

Signature____Amal Adam Lbrahim______